Abstract
Methods This is a retrospective audit, data being collected over a period of 32 months between January 2010 and August 2012. All individuals received routine intravenous antimicrobial prophylaxis. Postoperative wound-infection rates as well as routine outcomes were compared. Information for the study was obtained from the cardiac surgical Patients Analysis and Tracking System (PATS) database and from hospital records.
Highlights
From 23rd World Congress of the World Society of Cardio-Thoracic Surgeons Split, Croatia. 12-15 September 2013. The purpose of this audit is to review the impact of local administration of Gentamicin – Collagen Sponge (Collatamp) on the incidence of sternal wound infection in high risk cardiac surgery patients within our hospital
Out of 2238 patients that were audited Collatamp was used in 122 patients (5%), of which 5% developed post – operative sternal wound infection
The rate of sternal wound infection in Collatamp cohort was raised (5%) in comparison with non-Collatamp cohort (3%), the length of stay in hospital was shorter in Collatamp patients
Summary
The purpose of this audit is to review the impact of local administration of Gentamicin – Collagen Sponge (Collatamp) on the incidence of sternal wound infection in high risk cardiac surgery patients within our hospital. Impact of Gentamicin - Collagen Sponge (Collatamp) on the incidence of sternal wound infection in high risk cardiac surgery patients From 23rd World Congress of the World Society of Cardio-Thoracic Surgeons Split, Croatia. Background The purpose of this audit is to review the impact of local administration of Gentamicin – Collagen Sponge (Collatamp) on the incidence of sternal wound infection in high risk cardiac surgery patients within our hospital.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
